Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and efficacy of Testogel® 50mg/5g gel administered once daily (QD, morning dosing) compared to placebo administered once daily (QD, morning dosing), for 3 months, in hypogonadal men with testosterone deficiency being confirmed by clinical features and biochemical tests. For men with hypogonadism, treatment aims to restore testosterone levels to normal physiological range.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
240 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Ellen Dhoore
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal